Boston Scientific Raises 2025 Guidance After Strong Q3

Boston Scientific reported Q3 2025 revenue of about $5.07 billion (roughly 20% reported, 15.3% organic) and adjusted EPS of $0.75, beating consensus and company guidance. Management raised full-year 2025 sales guidance to roughly 20% reported growth (≈15.5% organic) and lifted adjusted EPS guidance to $3.02–$3.04, while guiding Q4 EPS of $0.77–$0.79 and sales of $5.22–$5.31 billion. The company has reorganized into two reportable segments — MedSurg and Cardiovascular — with MedSurg sales near $1.72 billion and strength in endoscopy and neuromodulation. Key franchises showed accelerating momentum, led by WATCHMAN (≈35% organic growth) and FARAPULSE/pulsed-field ablation, and gross margin expansion plus SG&A leverage helped results. Management said it expects an approximately $100 million tariff headwind in 2025. Several brokers (Canaccord, UBS, Needham, TD Cowen) maintained or raised targets and Buy ratings as shares traded modestly higher amid analyst optimism and valuation considerations.